

Contents

Preface xvii

1	Analytical Validation Within the Pharmaceutical Lifecycle	1
	<i>Phil Nethercote and Joachim Ermer</i>	
1.1	Development of Process and Analytical Validation Concepts	1
1.2	Alignments Between Process and Analytics: Three-Stage Approach	3
1.3	Predefined Objectives: ATP	5
1.4	Analytical Lifecycle	7
	References	9

Part I Prerequisites 13

2	Data Governance, Data Integrity, and Data Quality	15
	<i>R.D. McDowall and C. Burgess</i>	
2.1	Terminology Used in This Chapter	15
2.1.1	Data Governance	15
2.1.2	Data Integrity	15
2.1.3	Data Quality	15
2.2	Data Governance and Data Integrity Model	16
2.2.1	Descriptions of the Four Levels in the Model	16
2.2.2	Foundation – Data Governance	17
2.2.2.1	Senior Management Involvement	18
2.2.2.2	Policies and Procedures Need To Be in Place	18
2.2.2.3	Roles and Responsibilities	18
2.2.2.4	Quality Culture and Working Environment	19
2.2.2.5	Outsourcing Analysis	19
2.2.2.6	Quality Oversight	19
2.2.3	Level 1: Analytical Instrument Qualification and System Validation (AIQSV)	19
2.2.4	Level 2: Analytical Procedure Lifecycle	20
2.2.5	Level 3: Right Analysis for the Right Analytical Result	20
2.2.6	Quality Oversight for Data Integrity	20

2.3	Interaction Between Levels 1 and 2	21
2.4	Overview of Data Integrity	21
2.5	ALCOA Criteria for Data Integrity	22
2.6	Understanding Level 3: Right Analysis for the Right Reportable Result	23
2.6.1	Analytical Procedure	23
2.6.2	Trained Analysts Working in an Open Culture	23
2.6.3	Instruments and Systems Used	24
2.6.4	Sample Preparation	25
2.6.5	Time Synchronisation	25
2.6.6	Digitalisation of Sample Preparation	26
2.6.7	Instrumental Analysis by Chromatography	26
2.6.8	Peak Integration	27
2.6.9	Calculation of the Reportable Result	27
2.7	Second-Person Review	28
2.8	Summary	30
	References	30
3	Analytical Instrument Qualification and System Validation Lifecycle	35
	<i>C. Burgess and R.D. McDowall</i>	
3.1	Data Integrity and Data Quality in a GMP Environment	35
3.1.1	Criteria for Data Quality	35
3.1.2	Regulatory Rationale for Qualified Analytical Instruments and Validated Systems	37
3.2	AIQSV Approach as an Essential Part of the Analytical Procedure Lifecycle	37
3.3	USP General Chapter <1058>	38
3.3.1	Data Quality Triangle	39
3.3.2	AIQ Lifecycle: The 4Qs Model	39
3.3.3	Risk-Based Classification of Apparatus, Instruments, and Systems	40
3.3.4	Roles and Responsibilities for AIQ	42
3.3.5	Software Validation for Group B and C Systems	43
3.4	Enhancement of <1058> and Harmonization of a Risk-Based Approach to Instruments and Systems with GAMP	43
3.4.1	Increased Granularity of USP <1058> Groups	43
3.4.2	Clarification of AIQ Terminology	44
3.4.3	A Continuum of Analytical Apparatus, Instruments, and Systems	44
3.4.4	Mapping USP <1058> Instrument Groups to GAMP Software Categories	45
3.4.5	Enhanced Data Quality Triangle	45
3.5	Risk-Based Approaches to Analytical Instrument and System Qualification [3]	45
3.5.1	Expanded <1058> Instrument and System Categories	46
3.5.1.1	Group A – Apparatus	46

3.5.1.2	Group B – Instruments	47
3.5.1.3	Group C – Systems	48
3.5.2	Examples of Possible Lifecycle Activities for the Eight Enhanced Categories	48
	References	49

4 Continued HPLC Performance Qualification 51

Hermann Wätzig and Neil J. Lander

4.1	Introduction	51
4.1.1	The Importance of Analytical Instrument Qualification	51
4.1.2	Terms and Definitions	51
4.1.3	Continued Performance Qualification: More by Less	53
4.2	Development of the Revised OQ/PQ Parameters List	53
4.3	Transfer of Modular Parameters into the Holistic Approach	55
4.3.1	Autosampler	55
4.3.2	Solvent Delivery System	55
4.3.3	Detector	56
4.4	OQ/PQ Data in Comparison with SST Data	58
4.5	Performance Monitoring: Trending Plots/Control Charts	59
4.5.1	Automated Limit Checking	59
4.6	General Procedure for cPQ	61
4.7	Example	65
4.8	Concluding Remarks	66
	Acknowledgment	67
	References	67

Part II Establishment of Measurement Requirements 69

5 Analytical Target Profile 71

Brent Harrington

5.1	Introduction	71
5.2	Components of an ATP	72
5.3	The Probability Statements	73
5.4	Metrics for Assessment	74
5.5	Summary	76
	Acknowledgments	77
	References	77

6 Decision Rules and Fitness for Intended Purpose 79

Jane Weitzel

6.1	Introduction	79
6.2	Defining the Fitness for Intended Purpose	80
6.3	Decision Rules	81

6.4	Overview of Process to Develop Requirements for Procedure Performance	82
6.5	Decision Rules and Compliance	82
6.6	Calculating Target Measurement Uncertainty	83
6.6.1	Coverage Factor, k , and Data Distributions	85
6.7	Types of Decision Rules	86
6.7.1	Decision Rules That Use Guard Bands	87
6.7.2	Decision Rules That Use Transition Rules	88
6.8	Target Measurement Uncertainty in the ATP	88
6.8.1	Cost of Analysis	89
6.9	Bias and Uncertainty in a Procedure	89
6.10	ATP and Key Performance Indicators	89
6.11	Measurement Uncertainty	90
6.11.1	What Uncertainty Is	90
6.11.2	Reporting Measurement Uncertainty	91
6.11.3	How Uncertainty Is Estimated	92
6.11.3.1	Step 1. Specify the Measurand	92
6.11.3.2	Step 2. Identify Uncertainty Components and Data Sources	93
6.11.3.3	Step 3. Quantify the Uncertainty Components	93
6.11.3.4	Step 4. Calculate the Combined Uncertainty	94
6.11.3.5	Step 5. Calculate the Expanded Uncertainty	94
6.11.4	Uncertainty Contains All Sources of Random Variability	94
6.12	Example	94
6.13	Conclusion	95
	References	96
7	Performance Characteristics of Analytical Procedures	97
	<i>Joachim Ermer</i>	
7.1	Precision	98
7.1.1	The Normal Distribution and its Parameters	99
7.1.1.1	But How Do I Know that My Analysis Results Are Normally Distributed?	100
7.1.1.2	So Why Is the Normal Distribution that Popular?	100
7.1.1.3	Student- t -Distribution	104
7.1.1.4	Confidence Intervals	106
7.1.2	The Log-normal Distribution	108
7.1.3	Normal, Not-normal, and Out-of Specification (OOS)	109
7.1.3.1	Out-of-Specification (OOS) Results	111
7.1.4	Precision Levels	112
7.1.4.1	System or Instrument Precision	112
7.1.4.2	Repeatability	113
7.1.4.3	Intermediate Precision and Reproducibility	114
7.1.4.4	Precision of the Reportable Result	116
7.1.5	Calculation of Precisions and Variances	121
7.1.5.1	Analysis of Variances (ANOVA)	122

7.1.5.2	Calculation of Precision from Linear Regression	125
7.1.5.3	Measurement Uncertainty (Error Propagation)	125
7.1.6	Concentration Dependency of Precision	127
7.1.7	Precision Acceptance Criteria	130
7.1.7.1	Acceptable Precision for Assay	130
7.1.7.2	Acceptable Precision for Impurities and Minor Components	136
7.1.7.3	Precisions Benchmarks	137
7.1.8	Precision and Reportable Range	146
7.1.9	Precision Highlights	146
7.2	Accuracy	147
7.2.1	Inference from Precision, Response, and Specificity	148
7.2.2	Comparison	149
7.2.2.1	Significance Tests	149
7.2.2.2	Equivalence Tests	151
7.2.2.3	Direct Comparison (Point Estimate)	152
7.2.2.4	Comparison Examples	153
7.2.3	Spiking Studies (Recovery)	155
7.2.3.1	Percentage Recovery	155
7.2.3.2	Recovery Function	156
7.2.3.3	Standard Addition	157
7.2.3.4	Impurities/Degradants	157
7.2.4	Combined Evaluation of Accuracy and Precision	160
7.2.5	Acceptance Criteria	164
7.2.6	Stability of Sample and Reference Standard Solutions	165
7.2.7	Accuracy Highlights	166
7.3	Specificity/Selectivity	167
7.3.1	Selective Detection	168
7.3.2	Selective Sample Preparation	168
7.3.3	Stress Samples	169
7.3.4	Demonstration of Specificity/selectivity by Accuracy	170
7.3.5	Chromatographic Resolution	170
7.3.6	Peak Purity (Co-elution)	171
7.3.6.1	Re-chromatography	171
7.3.6.2	Diode Array Detection	172
7.3.6.3	LC-MS	172
7.3.7	Specificity/selectivity Highlights	175
7.4	Response (Calibration Model)	175
7.4.1	Unweighted Linear Regression	177
7.4.1.1	Prerequisites	177
7.4.1.2	Confidence and Prediction Intervals	179
7.4.1.3	Graphical Evaluation of the Calibration Model	180
7.4.1.4	Numerical Regression Parameters	182
7.4.1.5	Statistical Linearity Tests	183
7.4.1.6	Evaluation of the Intercept (Absence of Systematic Errors)	186
7.4.2	Weighted Linear Regression	187

- 7.4.3 Appropriate Calibration Models 189
 - 7.4.3.1 Optimal Concentration for Single-point Calibration in Case of Impurity Testing 189
 - 7.4.3.2 Area% Quantitation 190
 - 7.4.3.3 Matrix Impact 191
- 7.4.4 Non-linear Response 191
- 7.4.5 Calibration Highlights 192
- 7.5 Detection and Quantitation Limits 193
 - 7.5.1 Requirements in Pharmaceutical Impurity Determination 194
 - 7.5.1.1 General Quantitation Limit 194
 - 7.5.1.2 Intermediate Quantitation Limit 195
 - 7.5.2 Approaches Based on the Blank 195
 - 7.5.3 Determination of DL/QL from Linear Response 198
 - 7.5.3.1 Standard Deviation of the Response 200
 - 7.5.3.2 95% Prediction Interval of the Regression Line 201
 - 7.5.3.3 Approach Based on German Standard DIN 32645 203
 - 7.5.3.4 From the Relative Uncertainty 203
 - 7.5.4 Accuracy and Precision-based Approaches 204
 - 7.5.5 Comparison of the Various Approaches 204
 - 7.5.6 Quantitation Limit Highlights 205
- Acknowledgments 205
- References 206

Part III Method Design and Understanding 217

- 8 ICHQ14 Analytical Procedure Development 219**
Phil Borman (GSK), Peter Hamilton (AZ), and Jean-François Dierick (GSK)
 - 8.1 Introduction 219
 - 8.2 The ATP 220
 - 8.3 Connection Between Product and Analytical Procedure Understanding 222
 - 8.4 Prior and Platform Knowledge 223
 - 8.5 Robustness and Method Operable Design Region (MODR) 226
 - 8.6 Link and Impact with Analytical Procedure Validation 227
 - 8.7 Analytical Procedure Control Strategy and Ongoing Procedure Performance Verification 228
 - 8.8 Lifecycle Strategy Including Enhanced Approaches in Submission 229
 - 8.9 Summary 232
 - References 233
- 9 Method Selection, Development, and Optimization 237**
Melissa Hanna-Brown, Roman Szucs, and Brent Harrington
 - 9.1 Introduction 237
 - 9.2 Method Selection 239

9.3	Method Development	240
9.4	Method Optimization	251
	Acknowledgments	262
	References	262
10	Multivariate Analytical Procedures	265
	<i>Wei Meng and Phil Borman</i>	
10.1	Introduction	265
10.1.1	Use of Multivariate Analytical Procedures in the Pharmaceutical Industry	267
10.1.1.1	Product and Process Design Phase	267
10.1.1.2	Control Strategy Development Phase	268
10.1.1.3	Process Validation and Lifecycle Strategy Phase	268
10.2	Sampling and Data Quality	269
10.3	Development of Multivariate Models	271
10.3.1	Data Preprocessing	271
10.3.2	Variable Selection	273
10.3.3	Exploratory Data Analysis	275
10.3.3.1	Principal Component Analysis	275
10.3.3.2	Outliers Detection and Handling	278
10.3.3.3	Cluster Analysis	279
10.3.4	Model Calibration	281
10.3.4.1	Quantitative Modeling	281
10.3.4.2	Qualitative Modeling	284
10.4	Model Optimization and Validation	286
10.4.1	Cross-Validation	286
10.4.2	Model Performance Assessment	288
10.5	Model Maintenance and Lifecycle Management	289
10.5.1	Ongoing Verification	290
10.5.1.1	Ordinary Maintenance	291
10.5.1.2	Evaluation of Triggers	291
10.5.2	Review Process	291
10.5.2.1	Model Update Assessment	292
10.5.2.2	Model Update Approval	292
10.5.2.3	New Model Version Development and Validation	292
10.5.3	Model Implementation Management	292
10.6	Summary	293
	Acknowledgments	293
	References	293
11	Case Study: Robustness Investigations	301
	<i>Gerd Kleinschmidt and Birgit Niederhaus</i>	
11.1	Introduction	301
11.2	General Considerations in the Context of Robustness Testing	302
11.3	Examples of Computer-Assisted Robustness Studies	304

11.3.1	Robustness Testing Based on Chromatography Modeling Software	305
11.3.2	Robustness Testing Based on Experimental Design	312
	Acknowledgment	337
	References	337

12 Risk Assessment and Analytical Procedure Control Strategy 343

Phil Nethercote

12.1	Background	343
12.2	Risk Management Process	343
12.3	ICH Q9	344
12.4	Using Risk Management to Develop a Control Strategy	345
12.4.1	Risk Identification/Hazard Identification	345
12.4.2	Risk Analysis	347
12.4.3	Risk Evaluation and Control	348
12.5	Analytical Procedure Control Strategy	349
	References	349

Part IV Method Performance Qualification 351

13 ICH Q2(R2): Validation of Analytical Procedures 353

Joachim Ermer

13.1	How to Read This Chapter	354
13.2	Introduction	354
13.2.1	Interpretation	354
13.3	General Considerations for Analytical Procedure Validation	354
13.3.1	New	355
13.3.2	Interpretation	355
13.3.3	Analytical Procedure Validation Study	356
13.3.4	New	356
13.3.5	Interpretation	356
13.3.6	Validation During the Lifecycle of an Analytical Procedure	356
13.3.6.1	Interpretation	357
13.3.7	Reportable Range	357
13.3.7.1	Interpretation	357
13.3.8	Demonstration of Stability-indicating Properties	358
13.3.8.1	Interpretation	358
13.3.9	Considerations for Multivariate Analytical Procedures	358
13.4	Validation Tests, Methodology, and Evaluation	359
13.4.1	Specificity/Selectivity	359
13.4.1.1	New	359
13.4.1.2	Interpretation	360
13.4.2	Range	360
13.4.2.1	General Considerations	360

13.4.2.2	Response	361
13.4.2.3	Validation of Lower Range Limits	363
13.4.3	Accuracy and Precision	364
13.4.3.1	Accuracy	364
13.4.3.2	Precision	365
13.4.3.3	Combined Approaches for Accuracy and Precision	366
13.4.4	Robustness	367
13.4.4.1	New	367
13.5	Annex 2: Illustrative Examples for Analytical Techniques	367
13.5.1	Interpretation	368
13.5.2	Some Specific Gaps	369
13.6	Conclusion	370
	References	371
14	Case Study: Validation of a High-performance Liquid Chromatography (HPLC) Method for Identity, Assay, and Degradation of Products	373
	<i>Gerd Kleinschmidt and Birgit Niederhaus</i>	
14.1	Introduction	373
14.2	Experimental	375
14.3	Validation Summary	377
14.4	Validation Methodology	380
14.4.1	Specificity	380
14.4.2	Calibration Model	382
14.4.2.1	Calibration Model of MC	382
14.4.2.2	Calibration Model of DP1	384
14.4.3	Accuracy	384
14.4.3.1	Accuracy of MC	384
14.4.3.2	Accuracy of DP1 (Degradation Products)	384
14.4.4	Precision	385
14.4.4.1	System Precision	386
14.4.4.2	Repeatability	387
14.4.4.3	Intermediate Precision	387
14.4.5	LOQ	388
14.4.6	Reportable Range	389
14.5	Conclusion	389
	References	390
15	Case Study: Design and Qualification of a Delivered Dose Uniformity Procedure for a Pressurized Metered Dose Inhaler with a Focus on Sample Preparation	391
	<i>Andy Rignall</i>	
15.1	Introduction	391

- 15.1.1 Analytical Procedures for Complex Dosage Forms 391
- 15.1.2 Human and Environmental Factors Associated with Complex Laboratory Procedures 391
- 15.1.3 Delivered Dose Uniformity Testing for Inhalation Products 392
- 15.2 Designing a DDU Procedure that will Meet an ATP 392
 - 15.2.1 Risk Assessment and Classification 394
 - 15.2.1.1 Device Preparation 394
 - 15.2.1.2 Dose Collection 394
 - 15.2.1.3 Experimental Factors Associated with Dose Collection 396
 - 15.2.1.4 Shaking Profile Experiments 396
 - 15.2.1.5 Actuation Profile Experiments 397
 - 15.2.2 Noise Factors Associated with Dose Collection 398
 - 15.2.3 Dose Recovery and Sample Preparation 400
 - 15.2.4 Automated DDU Procedure 400
 - 15.2.4.1 Automated Shaking 400
 - 15.2.4.2 Automated Actuation 400
 - 15.2.4.3 Automated DDU Procedure 401
 - 15.2.5 Results Calculation and Reporting 401
- 15.3 Performance Characteristics of the DDU Procedure 401
- 15.4 Qualification of the DDU Procedure 402
- 15.5 Summary of the Analytical Procedure Control Strategy for a DDU Procedure 402
 - Acknowledgments 403
 - References 403

- 16 Case Study: Validation of a Bioassay Method 405**
 - Andrea Sobjak*
 - 16.1 Introduction 405
 - 16.2 Material Considerations 407
 - 16.3 Study Design 407
 - 16.4 Specificity/Selectivity 410
 - 16.4.1 Stability-indicating Properties 410
 - 16.5 Accuracy 411
 - 16.6 Precision 412
 - 16.6.1 Intermediate Precision 412
 - 16.6.2 Repeatability 413
 - 16.6.3 Reproducibility 415
 - 16.7 Range 415
 - 16.8 Robustness 416
 - 16.9 Conclusion 417
 - Acknowledgments 417
 - References 418

17	Implementation of Compendial/Pharmacopeia Test Procedures	419
	<i>Pauline L. McGregor</i>	
17.1	Background of Pharmacopeia Procedures	419
17.2	How Pharmacopeia Methods Are Generated and Published	420
17.3	Challenges with Compendial Procedures and the Need to Verify	420
17.4	Using Pharmacopeia Procedures in a Laboratory for the First Time	421
17.5	Verification of Pharmacopeia Procedures	422
17.6	Integration of the Verification Process and the Lifecycle Approach	423
17.7	Implementation of a Pharmacopeia Procedure Using the Lifecycle Approach	424
17.7.1	Gather Knowledge	424
17.7.1.1	Define the Intended Purpose of the Procedure	424
17.7.1.2	Understand the Settings on your Instruments	425
17.7.1.3	Read the Monograph Carefully	425
17.7.1.4	Define an Analytical Procedure Control Strategy (APCS)	428
17.7.1.5	Run a Trial Study	428
17.7.1.6	Derive an ATP	429
17.7.1.7	Testing the Feasibility of the ATP	430
17.7.1.8	Finalizing the ATP	431
17.8	Performance Qualification	431
17.9	Conclusion	432
	References	432
18	Transfer of Analytical Procedures	435
	<i>Christophe Agut, Marion Berger, and Hugo Zuin</i>	
18.1	Transfer Process and Strategy	435
18.1.1	Regulatory and International Guidance	435
18.1.2	Transfer Process	440
18.1.2.1	Coordination of Transfer Activities	441
18.1.2.2	Transfer Strategy	441
18.1.2.3	Familiarization and Training	443
18.1.2.4	Design of Experimental Studies and Acceptance Criteria	444
18.1.2.5	Result Evaluation and Transfer Report	445
18.2	Comparative Testing	445
18.2.1	Equivalence-based Methodology	446
18.2.1.1	Principle	446
18.2.1.2	Interlaboratory Study	447
18.2.1.3	Transfer Endpoints	448
18.2.1.4	Acceptance Criteria for Equivalence Testing	449
18.2.1.5	Statistical Analysis (Equivalence Data Analysis Methods)	457

18.2.1.6	Decision Procedure	458
18.2.1.7	Illustration of the Approach on a Real Example	461
18.2.2	Direct Comparison	465
18.2.2.1	Precision	465
18.2.2.2	Accuracy	466
	References	468
19	Lifecycle Approach to Transfer of Analytical Procedures	471
	<i>Joachim Ermer</i>	
19.1	Facilitation of Transfer by Risk Assessment	472
19.2	Facilitation of Transfer by the APCS	472
19.3	“Lean” Transfer Strategy	473
19.4	Conclusion	474
	References	475
	Part V Ongoing Method Performance Verification	477
20	Continuous Improvements, Adjustments, and Changes	479
	<i>Dr. Phil W. Nethercote</i>	
20.1	Drivers for Change	479
20.2	Control of Change in the Pharmaceutical Industry	480
20.3	Implementing a Change	483
	References	484
21	Monitoring of Analytical Performance	487
	<i>Joachim Ermer</i>	
21.1	Sources of Performance Data and Information	488
21.1.1	System Suitability Test Parameters	490
21.1.2	Parameter from Calibration or Reference Standard Analysis	490
21.1.3	Parameter from Sample Analysis	491
21.1.4	Quality Control Samples (QCS)	491
21.1.5	Batch Results	491
21.1.6	Precisions from Stability	491
21.2	Systematic Monitoring Program	493
21.3	Analytical Performance Evaluation Tools	495
21.3.1	Visualization Charts	496
21.3.2	Average Performance Parameters	501
21.4	Assessment of Analytical Performance	503
21.4.1	Immediate Actions	503
21.4.2	Analytical Performance Review (APR)	504
21.5	Conclusion	508
	References	508
	Index	511